TG Therapeutics IncNASDAQ:TGTX
- LAST PRICE16.6750
- TODAY'S CHANGE (%)0.1050 (0.6337%)
- Bid / Lots16.6600/ 3
- Ask / Lots16.6900/ 14
- Open / Previous Close16.7100 / 16.5700
- Day Range
- 52 Week Range
- Volume666,627
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TGTX |
|---|---|---|
| 09:32 ET | 11760 | 16.67 |
| 09:34 ET | 8840 | 16.56 |
| 09:36 ET | 1330 | 16.43 |
| 09:38 ET | 1822 | 16.4301 |
| 09:39 ET | 1353 | 16.49 |
| 09:41 ET | 7693 | 16.6 |
| 09:43 ET | 15118 | 16.7 |
| 09:45 ET | 13983 | 16.72 |
| 09:48 ET | 33218 | 16.78 |
| 09:50 ET | 8523 | 16.67 |
| 09:52 ET | 11315 | 16.655 |
| 09:54 ET | 6011 | 16.66 |
| 09:56 ET | 4615 | 16.61 |
| 09:57 ET | 20997 | 16.64 |
| 09:59 ET | 1200 | 16.64 |
| 10:01 ET | 10633 | 16.68 |
| 10:03 ET | 3380 | 16.61 |
| 10:06 ET | 35897 | 16.66 |
| 10:08 ET | 5612 | 16.645 |
| 10:10 ET | 9158 | 16.68 |
| 10:12 ET | 4029 | 16.67 |
| 10:14 ET | 8398 | 16.7599 |
| 10:15 ET | 14684 | 16.83 |
| 10:17 ET | 17102 | 16.87 |
| 10:19 ET | 4706 | 16.925 |
| 10:21 ET | 8902 | 16.9072 |
| 10:24 ET | 5867 | 16.91 |
| 10:26 ET | 1300 | 16.905 |
| 10:28 ET | 6671 | 16.9 |
| 10:30 ET | 300 | 16.89 |
| 10:32 ET | 8694 | 16.9195 |
| 10:33 ET | 8453 | 16.95 |
| 10:35 ET | 3201 | 16.935 |
| 10:37 ET | 3516 | 16.8236 |
| 10:39 ET | 1254 | 16.815 |
| 10:42 ET | 13393 | 16.81 |
| 10:44 ET | 13012 | 16.71 |
| 10:46 ET | 21304 | 16.72 |
| 10:48 ET | 5443 | 16.7 |
| 10:50 ET | 2580 | 16.68 |
| 10:51 ET | 7785 | 16.66 |
| 10:53 ET | 3799 | 16.659 |
| 10:55 ET | 490 | 16.64 |
| 10:57 ET | 1400 | 16.61 |
| 11:00 ET | 2651 | 16.631 |
| 11:02 ET | 20414 | 16.62 |
| 11:04 ET | 27322 | 16.67 |
| 11:06 ET | 5393 | 16.72 |
| 11:08 ET | 7584 | 16.7497 |
| 11:09 ET | 11456 | 16.74 |
| 11:11 ET | 7265 | 16.64 |
| 11:13 ET | 1425 | 16.62 |
| 11:15 ET | 9473 | 16.69 |
| 11:18 ET | 1592 | 16.694 |
| 11:20 ET | 3500 | 16.665 |
| 11:22 ET | 1650 | 16.64 |
| 11:24 ET | 1921 | 16.7 |
| 11:26 ET | 3440 | 16.73 |
| 11:27 ET | 2600 | 16.72 |
| 11:29 ET | 9630 | 16.7095 |
| 11:31 ET | 2928 | 16.69 |
| 11:33 ET | 325 | 16.7 |
| 11:36 ET | 3813 | 16.69 |
| 11:38 ET | 1535 | 16.7 |
| 11:40 ET | 2027 | 16.67 |
| 11:42 ET | 17814 | 16.69 |
| 11:44 ET | 1950 | 16.68 |
| 11:45 ET | 404 | 16.67 |
| 11:47 ET | 4033 | 16.62 |
| 11:49 ET | 9600 | 16.63 |
| 11:51 ET | 800 | 16.625 |
| 11:54 ET | 2572 | 16.64 |
| 11:56 ET | 322 | 16.64 |
| 11:58 ET | 3637 | 16.66 |
| 12:00 ET | 901 | 16.68 |
| 12:02 ET | 300 | 16.675 |
Jun 11, 2024
Jun 7, 2024
TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference, from 7:50AM ET on Friday Jun 07, 2024 by Dow Jones
7:50AM ET on Friday Jun 07, 2024 by Dow Jones
Jun 3, 2024
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference, from 7:30AM ET on Monday Jun 03, 2024 by Dow Jones
7:30AM ET on Monday Jun 03, 2024 by Dow Jones
May 31, 2024
May 28, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
TG Therapeutics Inc | 2.6B | 75.6x | --- |
ADMA Biologics Inc | 2.4B | -528.2x | --- |
Twist Bioscience Corp | 2.9B | -15.0x | --- |
MorphoSys AG | 2.7B | -5.4x | --- |
Arrowhead Pharmaceuticals Inc | 3.1B | -5.7x | --- |
Vericel Corp | 2.0B | 4,433.1x | --- |
Company Information
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Contact Information
- Headquarters
- 3020 Carrington Mill Blvd., Suite 475MORRISVILLE, NC, United States 27560-5435
- Phone
- 212-554-4484
- Fax
- 212-554-4531
Executives
- Chairman of the Board, President, Chief Executive Officer
- Michael Weiss
- Chief Financial Officer, Treasurer, Corporate Secretary
- Sean Power
- Lead Independent Director
- Laurence Charney
- Independent Director
- Yann Echelard
- Independent Director
- Kenneth Hoberman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.6B |
|---|---|
Revenue (TTM) | $289.3M |
Shares Outstanding | 154.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.22 |
EPS | $0.22 |
Book Value | $1.06 |
P/E Ratio | 75.6x |
Price/Sales (TTM) | 8.9 |
Price/Cash Flow (TTM) | 61.9x |
Operating Margin | 16.71% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
